Article

Sydney Morning HeraldSydney Morning Herald on 2021-03-18 02:06

AstraZeneca concerns can’t dent Korean partner’s stunning market debut

SK Bioscience saw its shares gain by its 160 per cent daily limit despite concerns over side effects of AstraZeneca Plc’s COVID-19 vaccine.

Related news